Elevance Health (ELV) Stock Forecast & Price Target

$366.30 -7.00 (-1.88%)

(As of 12/17/2024 ET)

Elevance Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
2

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Elevance Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 2 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for ELV.

Consensus Price Target

$539.20
47.20% Upside

According to the 16 analysts' twelve-month price targets for Elevance Health, the average price target is $539.20. The highest price target for ELV is $649.00, while the lowest price target for ELV is $478.00. The average price target represents a forecasted upside of 47.20% from the current price of $366.30.

Get the Latest News and Ratings for ELV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Elevance Health and its competitors.

ELV Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$539.20	$539.20	$604.29	$565.82
Forecasted Upside	47.20% Upside	34.57% Upside	12.32% Upside	21.47% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

How this >10-cent coin is going to outperform Bitcoin (Ad)

Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…

#1 FREE Crypto for 2024

ELV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ELV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Elevance Health Stock vs. The Competition

Type	Elevance Health	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	47.22% Upside	28,526.48% Upside	12.04% Upside
News Sentiment Rating	Positive News See Recent ELV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	Mizuho 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$585.00 ➝ $505.00	+21.18%
11/4/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$593.00 ➝ $495.00	+19.56%
10/23/2024	Morgan Stanley 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$643.00 ➝ $551.00	+31.24%
10/22/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$622.00 ➝ $501.00	+19.06%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$589.00 ➝ $484.00	+12.56%
10/18/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$485.00	+12.18%
Could this be the hottest crypto discovery of all time? (Ad) I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free… If you want in, Just Click Here
10/18/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fidel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
10/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$605.00 ➝ $555.00	+28.06%
10/18/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$585.00 ➝ $478.00	+9.02%
10/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$620.00 ➝ $520.00	+18.60%
10/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$600.00 ➝ $485.00	+8.72%
10/18/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$646.00 ➝ $530.00	+1.89%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$628.00 ➝ $631.00	+24.00%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$649.00	+28.38%
4/19/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$602.00 ➝ $604.00	+15.01%
7/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
4/27/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/21/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$565.00 ➝ $550.00	+20.90%
4/20/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$571.00 ➝ $575.00	+25.73%
1/26/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$580.00	+17.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:48 AM ET.

ELV Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Elevance Health is $539.20, with a high forecast of $649.00 and a low forecast of $478.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevance Health in the last year. There is currently 1 sell rating, 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ELV shares.
: According to analysts, Elevance Health's stock has a predicted upside of 47.20% based on their 12-month stock forecasts.
: Over the previous 90 days, Elevance Health's stock had 1 downgrade by analysts.
: Elevance Health has been rated by research analysts at Argus, Barclays, Cantor Fitzgerald, Mizuho, Morgan Stanley, Raymond James, Royal Bank of Canada, Stephens, TD Cowen, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Elevance Health more than other "medical" companies. The consensus rating score for Elevance Health is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ELV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Will the Nasdaq 100 crash? (Ad)

In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!

Click here to get the details.

This page (NYSE:ELV) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elevance Health (ELV) Stock Forecast & Price Target